Chronic myeloid leukemia · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Dasatinib monotherapy Variant #01 | — | R 12 899 | 28d | — | — | ~2 | ~R 25 797 indirect | — |
Imatinib monotherapy Variant #16 | — | R 1 401 | 28d | ~20.0 mo | ~53.0 mo | ~2 | ~R 2 801 PFS proxy · indirect | 8 |
Hydroxyurea and Plicamycin Variant #01 Partial | — | R 198 | 21d | — | — | ~1 | ~R 198 indirect | — |
Vincristine and Prednisone Variant #01 | — | R 183 | 5d | — | — | ~1 | ~R 183 indirect | — |
Bosutinib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
5 of 5 regimens shown